Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti‐tumour necrosis factor α agents: an open‐label observational study

Podobne zapisy

• Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
  od: Finckh, A, i wsp.
  Wydane: (2010)
• Evidence for differential acquired drug resistance to anti‐tumour necrosis factor agents in rheumatoid arthritis
  od: Finckh, A, i wsp.
  Wydane: (2006)
• Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland
  od: Finckh, A, i wsp.
  Wydane: (2020)
• Rituximab for Refractory Rheumatoid Arthritis: A 24-Week Open-Label Prospective Study
  od: Ho, Ling Yin, i wsp.
  Wydane: (2007)
• Tumour necrosis factor blockade in rheumatoid arthritis
  od: Breedveld, Ferdinand C
  Wydane: (2001)